J.P. Morgan Comments On BioMemetic Therapeutics Bone Graft Vote

According to J.P. Morgan, BioMimetic Therapeutics BMTI has its work cut out for it. J.P. Morgan said that after a long day of debate, BioMimetic's Augment bone graft received a marginally favorable FDA panel vote Thursday evening. “The panel (n=18) voted on each of: (1) safety; (2) efficacy; and finally (3) the overall risk benefit profile of Augment. The safety vote was 12-6 in favor, while the efficacy and overall vote were a closer 10-8 in support of BMTI's data package.” BioMimetic Therapeutics closed yesterday at $4.68.